(UroToday.com) At this year’s European Society for Medical Oncology (ESMO) 2020 Virtual Congress, Dr. Ajjai Alva presented the final results from KEYNOTE-361, a trial of pembrolizumab +/- chemotherapy in advanced urothelial carcinoma.
(UroToday.com) Immune checkpoint blockade therapy by blocking PD-1/PD-L1 axis signaling is approved in advanced urothelial cancers in a few settings: (1) first-line therapy for platinum-ineligible patients, (2) first-line therapy in cisplatin-ineligible patients with high PD-L1 expression, (3) maintenance therapy for patients who do not progress with first-line chemotherapy, and (4) as subsequent therapy for patients progressing […]
(UroToday.com) Dr. Richard Cathomas discussed presentations of the KEYNOTE-361 (LBA23) and the DANUBE (697O) trials.
(UroToday.com) The PD-1 inhibitor pembrolizumab has shown antitumor activity in patients with heavily pre-treated, PD-L1-positive advanced prostate cancer and in PD-L1-positive and PD-L1-negative patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel who received ≥ 1 next-generation hormonal agent 1, 2. The mechanisms of action of pembrolizumab and enzalutamide might be complementary, leading […]
(UroToday.com) After a primary germ cell testicular cancer diagnosis, the risk of a metachronous contralateral (second) testicular cancer is increased, with an estimated 15-20 year cumulative incidence of 1.9-3.9%. It is hypothesized that cisplatin-based chemotherapy reduces the occurrence of a metachronous contralateral germ cell testicular cancer. However, data regarding treatment details are lacking in previous […]
(UroToday.com) Penile cancer is rare with an incidence of <1 per 100,000 in Western industrialized nations. Metastatic penile squamous carcinoma is a very rare disease with poor outcomes (overall survival < 1 year) despite the use of platinum-based chemotherapy agents. There is limited real-world data on how these patients are managed in clinical practice and their […]
(UroToday.com) Dr. Cristina Suarez presented a discussion of two oral presentations: LBA26 (update on clinical data from studies of the oral HIF-2a MK-6482 in Von Hippel-Lindau disease-associated cancers), and 703MO (discussion of spatial genomics in clear cell renal cell carcinoma (RCC) evolution).
(UroToday.com) The first abstract discussed was LBA26 – Phase 2 Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau (VHL) Disease–Associated Clear Cell Renal Cell Carcinoma (ccRCC): Update on RCC and Non-RCC Disease.
(UroToday.com) Radium 223 (Ra223) is a bone-seeking, alpha-emitting radionuclide that has been shown to improve overall survival and time to skeletal-related events in men with metastatic castrate-resistant prostate cancer (mCRPC)1. In the prospective, phase 3, randomized trial (ERA 223), the combination of Ra 223, abiraterone acetate, and prednisolone was associated with an increased risk of […]
(UroToday.com) The overall incidence of human papillomavirus (HPV) DNA in penile cancer is 42-70%, which is lower than cervical carcinoma (~100%), and similar to vulvar carcinoma (~50%). HPV prevalence differs by histologic subtype in penile cancer, including 100% of the ‘warty’ subtype, 80% for basaloid, 34.9% for keratinizing squamous cell carcinoma, and 33% of verrucous carcinoma. […]
